Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Docetaxol; NSC 628503; RP 56976; Taxotere; XPR 6976; XRP-6976

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Roche; Sanofi; University of Iowa; University of Texas M. D. Anderson Cancer Center; West German Study Group
  • Class Antineoplastics; Imaging agents; Radiopharmaceutical diagnostics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer
  • Registered Solid tumours
  • Phase I/II Sarcoma
  • Discontinued Fallopian tube cancer; Pancreatic cancer; Peritoneal cancer

Most Recent Events

  • 26 Jan 2018 Sanofi completes a phase III trial in Head and neck cancer (Late stage disease, Neoadjuvant therapy, Combination therapy, Inoperable/Unresectable) in China (IV) (NCT00995293)
  • 22 Aug 2017 Genentech completes a phase I/II trial in Sarcoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, First-line therapy, Second-line therapy or greater, In adults, In the elderly) in USA (unspecified route) (NCT01106872)
  • 02 Jun 2017 Adverse events and efficacy data from the phase-II DECIDE trial in Head and neck cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top